Engagement of Consultant to Access the Treatment O...

FREE TRIAL

Get Access to 1 Million Global Tenders

You are Successfully Registered to zimbabwetenders!!

Email Id is already exist !!

Something went wrong !!

Publish Tenders

Click here to publish tender and gain more visibility worldwide.

Subscription Plans

Click here to upgrade to a Premium Plan.

100% Secure Payments

Tender Details

Download Tender Documents

Country: Ghana
Summary: Engagement of Consultant to Access the Treatment Outcomes Among Pediatric Hiv Patients on Dolutegravir (Dtg) -10Mg in Ghana
GHT Ref No: 77844534
Deadline: 13 Feb 2023
Competition: NCB
Financier: Self Financed
Purchaser Ownership: Public
Tender Value: 300.00
Notice Type: Tender
Document Ref. No.: GHSHQ/2023/CS/RFP/03
Purchaser's Detail :

Purchaser : GHANA HEALTH SERVICE
Greater Accra,Accra Metropolitan District
Contact Person : The Procurement Department Ghana Health Service, Headquarters Limp Fitting Centre, Tema Station Near Rent Control Pmb Ministries Accra
Phone : (233)(303) 973320
Email :info@ghs.gov.gh

Description :
Title : Engagement Of Consultant To Access The Treatment Outcomes Among Pediatric HIV Patients On Dolutegravir (DTG) -10mg In Ghana
Tender Type : NCT
Tender Description : Engagement Of Consultant To Access The Treatment Outcomes Among Pediatric HIV Patients On Dolutegravir (DTG) -10mg In Ghana.The Government of Ghana through the Ministry of Health/ Ghana Health Service (GHS) has received the Global Fund-s New Funding Model to support the implementation of the National HIV/AIDS Control Programme (NACP) activities within the current Strategic plan, 2021-2025.The WHO suggested dolutegravir (DTG) as a first-line ART treatment option for adult Persons Living with HIV (PLHIV) in low- and middle-income countries. After the effective roll out of DTG for adults in several countries including Ghana, WHO again recommended the use of DTG among pediatric clients. The new generic version of dolutegravir (DTG) called pediatric dolutegravir 10 mg dispersible tablets (pDTG) is appropriate for children living with HIV who are less than 4 weeks of age and weigh at least 3 kg but less than 20 kg. To enable GHS and NACP appreciate the effectiveness of this medication, technical support is being sought from applicants or consultants to undertake a study to assess the actual problems associated with the treatment outcomes among Pediatric HIV Patients on Dolutegravir (DTG) -10mg in Ghana.Lot 1 - Engagement Of Consultant To Access The Treatment Outcomes Among Pediatric HIV Patients On Doluteg...
Documents :